SWP
CBIO

Stratos Wealth Partners’s Crescent Biopharma CBIO Stock Holding History

Stratos Wealth Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-333
Closed -$58K – 1303
2023
Q2 		$58K Sell
333
-693
-68% -$116K ﹤0.01% 1170
2023
Q1 		$129K Buy
+1,026
New +$231K ﹤0.01% 1071

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stratos Wealth Partners's CBIO Position: Q3 2023 in Review

Stratos Wealth Partners sold out of Crescent Biopharma (CBIO) in Q3 2023, closing a stake of 333 shares — an estimated $58K sold.

Stratos Wealth Partners first reported a position in CBIO in Q1 2023 and held it in 2 quarters. The position peaked at $129K in Q1 2023. 49 funds tracked by Wall St. Rank hold CBIO as of Q3 2023.

  • Stratos Wealth Partners reported no remaining Crescent Biopharma position as of Q3 2023 after selling out during the quarter.
  • Stratos Wealth Partners sold 333 Crescent Biopharma shares in Q3 2023, an estimated $58K.
  • Stratos Wealth Partners first reported a position in Crescent Biopharma in Q1 2023 and held it in 2 quarters.
  • Stratos Wealth Partners's Crescent Biopharma position peaked at $129K in Q1 2023.
  • 49 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2023.

Based on Stratos Wealth Partners's 13F filing for Q3 2023, filed 24 Oct 2023.